Intranasal Ciclesonide for Treatment of Allergic Rhinitis in Children and Adolescents

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2012;18(5) 

In This Article

Abstract and Introduction


Ciclesonide nasal spray was first approved by the Food and Drug Administration (FDA) on October 20, 2006 as a hypotonic aqueous suspension (Omnaris®; Sunovion Pharmaceuticals, Inc.).[1–4] It is currently indicated for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and older, as well as perennial allergic rhinitis in adults and adolescents 12 years of age and older. Since its introduction, ciclesonide has become one of the most popular treatment options for allergic rhinitis, a condition affecting as much as 20% of the US population.

On January 20, 2012, the FDA approved a second ciclesonide intranasal product, Zetonna® from the same manufacturer.[5] This new formulation utilizes a hydrofluoroalkane (HFA) propellant which dispenses the drug in a fine dry mist. The resulting aerosol spray produces less run-off of the drug down the throat or out of the nose following administration, which may provide more accurate drug delivery and improved patient acceptance.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.